Page 110 - CIBEREHD2016-ENG

LEAD rESEArCHEr
Pastor Anglada, Marçal
Universidad de Barcelona
Facultad de Biología. Diagonal, 645
08028 Barcelona
(+34) 93 402 15 43 [email protected] group Website
GROUP MEMBERS
Staff members: Iglesias Garanto, Ingrid | Pérez Torras, Sandra Associated members: Casado Merediz, Francisco Javier
Main lines of research
• Role of the cellular transportome in oncogenesis and gastrointestinal inflammatory diseases.
We will dissect the interactome of membrane proteins whose expression is known to be altered in inflamed tissue and tumors. This project combines the “transceptor” concept with the analysis of the protein networks incorporating these membrane proteins. We anticipate that these networks are relevant to liver and gastrointestinal pathologies.
• Purinergic singaling in liver and gastrointestinal diseases.
The purinome and purinergic signaling are being studied in the context of liver and intestinal physiology, as well as under inflammatory and oncologic conditions.
• Molecular pharmacology and pharmacogenetics of drug transporters.
We will study drug-transporter interactions and the impact of genetic variability on transporter functionl. The ultimate goal is to understand how transporter expression patterns determine drug responsiveness.
• Generation of preclinical models to study newly developed anticancer drugs.
- Genetic engineering of cellular models for the preclinical assay of drug bioavailability.
Based upon the increasing interest of the pharmaceutical companies and regulatory agencies to establish preclinical assays of drug-transporter interaction, we are developing epithelial barrier models to anticipate pharmacokinetics interactions among drugs.
- New animal models for the study of new drugs against pancreatic adenocarcinoma.
The MPET laboratory has a platform of orthotopic models derived from human pancreatic adenocarcinomas, suitable for the preclinical assessment of novel antitumor therapies.
110
PROGRAMMES
P4